Details

Autor(en) / Beteiligte

• Han, Se young
• Mrózek, Krzysztof
• Voutsinas, Jenna
• Wu, Qian
• Morgan, Elizabeth A.
• Vestergaard, Hanne
• Ohgami, Robert
• Kluin, Philip M.
• Kristensen, Thomas Kielsgaard
• Pullarkat, Sheeja
• Møller, Michael Boe
• Schiefer, Ana-Iris
• Baughn, Linda B.
• Kim, Young
• Czuchlewski, David
• Hilberink, Jacobien R.
• Horny, Hans-Peter
• George, Tracy I.
• Dolan, Michelle
• Ku, Nam K.
• Arana Yi, Cecilia
• Pullarkat, Vinod
• Kohlschmidt, Jessica
• Salhotra, Amandeep
• Soma, Lori
• Bloomfield, Clara D.
• Chen, Dong
• Sperr, Wolfgang R.
• Marcucci, Guido
• Cho, Christina
• Akin, Cem
• Gotlib, Jason
• Broesby-Olsen, Sigurd
• Larson, Melissa
• Linden, Michael A.
• Deeg, H. Joachim
• Hoermann, Gregor
• Perales, Miguel-Angel
• Hornick, Jason L.
• Litzow, Mark R.
• Nakamura, Ryotaro
• Weisdorf, Daniel
• Borthakur, Gautam
• Huls, Gerwin
• Valent, Peter
• Ustun, Celalettin
• Yeung, Cecilia C.S.

Titel

Secondary cytogenetic abnormalities in core-binding factor AML harboring inv(16) vs t(8;21)

Ist Teil von

• Blood advances, 2021-05, Vol.5 (10), p.2481-2489

Ort / Verlag

United States: Elsevier Inc

Erscheinungsjahr

2021

Link zum Volltext

Quelle

Electronic Journals Library - Freely accessible e-journals

Beschreibungen/Notizen

• Patients with core-binding factor (CBF) acute myeloid leukemia (AML), caused by either t(8;21)(q22;q22) or inv(16)(p13q22)/t(16;16)(p13;q22), have higher complete remission rates and longer survival than patients with other subtypes of AML. However, ∼40% of patients relapse, and the literature suggests that patients with inv(16) fare differently from those with t(8;21). We retrospectively analyzed 537 patients with CBF-AML, focusing on additional cytogenetic aberrations to examine their impact on clinical outcomes. Trisomies of chromosomes 8, 21, or 22 were significantly more common in patients with inv(16)/t(16;16): 16% vs 7%, 6% vs 0%, and 17% vs 0%, respectively. In contrast, del(9q) and loss of a sex chromosome were more frequent in patients with t(8;21): 15% vs 0.4% for del(9q), 37% vs 0% for loss of X in females, and 44% vs 5% for loss of Y in males. Hyperdiploidy was more frequent in patients with inv(16) (25% vs 9%, whereas hypodiploidy was more frequent in patients with t(8;21) (37% vs 3%. In multivariable analyses (adjusted for age, white blood counts at diagnosis, and KIT mutation status), trisomy 8 was associated with improved overall survival (OS) in inv(16), whereas the presence of other chromosomal abnormalities (not trisomy 8) was associated with decreased OS. In patients with t(8;21), hypodiploidy was associated with improved disease-free survival; hyperdiploidy and del(9q) were associated with improved OS. KIT mutation (either positive or not tested, compared with negative) conferred poor prognoses in univariate analysis only in patients with t(8;21). •Cytogenetic abnormalities differ significantly and confer distinct prognostic impact in each subgroup of CBF-AML.•Survival was improved for patients with co-occurrence of inv(16) with trisomy 8 or t(8;21) with hyperdiploidy, hypodiploidy, and del(9p). [Display omitted]